Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 1 January 2026 - 6 January 2026

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

London, January 6, 2026, 09:03 GMT — Regular session GSK plc shares rose nearly 1% in early London trade on Tuesday after the drugmaker said Japan had approved its bronchial asthma treatment Exdensur. Shares were up 0.96% at 1,838 pence by 0830 GMT. sharecast.com The decision lands as investors weigh whether GSK’s next wave of respiratory launches can broaden growth beyond its established portfolio. Long-acting medicines that cut the number of injections can be a commercial lever, but they also have to win reimbursement and persuade patients and doctors to switch. The Japan approval followed a separate regulatory win in
6 January 2026
··
Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

New York, Jan 5, 2026, 14:59 EST — Regular session Thermo Fisher Scientific Inc shares rose about 2.4% in afternoon trading on Monday after Evercore ISI raised its price target to $650 from $610 and kept an “outperform” rating, a call that signals expectations for the stock to beat the broader market. The stock was last up 2.4% at $606.63, after swinging between $590.00 and $608.29 on volume of about 1.6 million shares. MarketScreener The move puts Thermo Fisher back on screens ahead of its late-January results, when investors will look for fresh clues on drugmaker and laboratory spending that
5 January 2026
···
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms

BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms

New York, January 5, 2026, 14:30 (EST) — Regular session BridgeBio Pharma shares slid 7.5% to $72.34 in afternoon trading on Monday after opening at $78.44 and touching $79.24 earlier in the session. The drop outpaced a roughly 2.2% decline in the SPDR S&P Biotech ETF, a broad gauge of U.S. biotech stocks. The move lands just ahead of a dense stretch of biotech investor events that can reshape positioning at the start of the year. For BridgeBio, the calendar puts fresh focus on a late-stage growth program and the company’s next set of talking points on its commercial heart
5 January 2026
··
Thermo Fisher (TMO) stock closes higher into 2026 — what to watch before Jan. 29 earnings

Thermo Fisher (TMO) stock closes higher into 2026 — what to watch before Jan. 29 earnings

NEW YORK, January 4, 2026, 19:53 ET — Market closed Thermo Fisher Scientific Inc shares closed Friday up about 2.3% at $592.51, beating the broader market’s modest advance in the first session of 2026. Reuters The move matters heading into Monday because investors are rotating from thin holiday trade into a January calendar packed with economic data and the start of earnings season. Thermo Fisher’s results later this month will be one of the first big readouts for life-science tools demand. Thermo Fisher Scientific Thermo Fisher is a bellwether for “life science tools” — lab instruments, consumables and services used
5 January 2026
···
Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

NEW YORK, Jan 3, 2026, 20:55 ET — Market closed Wave Life Sciences Ltd (WVE) shares closed down 6.2% on Friday at $15.95, ending the first full U.S. trading session of 2026 with a sharp pullback. The slide matters because Wave has become an event-driven obesity trade after a December clinical update on its experimental fat-loss drug drew heavy attention from biotech investors. With U.S. markets closed for the weekend, traders are now looking past Friday’s drop to the next scheduled clinical follow-ups and to how Wave’s recent fundraising affects the stock’s risk-reward into 2026. Nasdaq trading data showed WVE
4 January 2026
··
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next

Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next

NEW YORK, Jan 2, 2026, 14:37 ET — Regular session Shares of Spyre Therapeutics, Inc. slid about 7% on Friday, falling to $30.48 in afternoon trading after touching a session low of $30.11. The stock opened at $32.76 and was last down $2.28 on the day. The move left Spyre underperforming the broader biotech tape, with the SPDR S&P Biotech ETF down about 0.7% and the iShares Nasdaq Biotechnology ETF off about 0.2%. “Money managers are waiting to see … the vibe for the coming year,” said Thomas Martin, senior portfolio manager at Globalt, describing the first-session tone in U.S.
2 January 2026
··
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade

Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade

NEW YORK, Jan 2, 2026, 2:49 PM ET — Regular session Shares of Nuvation Bio Inc fell about 6.8% to $8.35 in afternoon trading on Friday, after opening at $8.97 and swinging between $9.13 and $8.30. About 3.3 million shares had changed hands. The decline stood out against a softer but steadier biotech tape. The SPDR S&P Biotech ETF was down about 0.7% and iShares Nasdaq Biotechnology ETF slipped about 0.2%, while the S&P 500 ETF was modestly higher and small caps outperformed. The stock’s slide comes as investors recalibrate risk in the first U.S. session of 2026, with strategists
2 January 2026
··
Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

NEW YORK, January 2, 2026, 14:13 ET — Regular session Wave Life Sciences Ltd shares slid on Friday, giving back part of last month’s obesity-driven run as the biotech sector wobbled in the first U.S. session of 2026. The stock was down about 8.5% at $15.55 as of 2:13 p.m. ET. The retreat matters because Wave has become a high-volatility obesity “story stock,” with investors trying to price the upside of an early-stage program against the risks that come with thin clinical data and heavy funding needs. The shares more than doubled on December 8 after the company posted interim
2 January 2026
··
INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

NEW YORK, Jan 2, 2026, 11:40 ET — Regular session Shares of Intelligent Bio Solutions Inc slid on Friday as investors digested the micro-cap medtech company’s $10 million private placement announced late Wednesday. The stock was down 12.1% at $8.38 by 11:25 a.m. ET. Benzinga The pullback comes after the stock more than doubled on Dec. 31 following news of a manufacturing partnership aimed at scaling production of its fingerprint-based drug screening reader. Nasdaq The timing matters because INBS is trying to ramp production and shore up supply as it targets a 2026 U.S. market entry, while also tapping capital
2 January 2026
··
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

NEW YORK, January 1, 2026, 21:17 ET — Market closed Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. New York Stock Exchange The year-end move matters because Cytokinetics is weeks away from its first full-scale commercial test. Investors have been valuing the biotech on clinical data and regulatory milestones; the next swing factor is execution in the field. In mid-December, the company said the U.S.
2 January 2026
·
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

NEW YORK, January 1, 2026, 18:59 ET — Market closed Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar. StockAnalysis+1 The pullback matters because CRISPR heads into 2026 with its first commercial product still early in launch and with investors seeking clearer signs of demand. The stock has tended to react sharply to shifts in sentiment around gene-editing drugmakers. Traders are also looking ahead to the next set of checkpoints: read-throughs from partner Vertex Pharmaceuticals, which
2 January 2026
······
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

NEW YORK, January 1, 2026, 16:58 ET — Market closed Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between $148.79 and $184.40 on volume of about 3.1 million shares. Businessinsider Why it matters now: priority review shortens the FDA’s review target to six months, versus 10 months under the standard process, pulling a key binary catalyst into the first
1 January 2026
···
1 … 6 7 8 9 10 … 25

Stock Market Today

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

7 February 2026
Stellantis shares plunged 23.7% to $7.28 Friday after the company disclosed about €22.2 billion in charges tied to a reset of its electric-vehicle strategy and said it will skip its 2026 dividend. The automaker flagged a preliminary net loss of €19–21 billion for the second half of 2025. Shares rose 1.6% in late after-hours trading. Investors await Feb. 26 results and a May 21 Investor Day.
Intel stock jumps on China server CPU delays as traders map the week ahead

Intel stock jumps on China server CPU delays as traders map the week ahead

7 February 2026
Intel shares rose 4.87% to $50.59 Friday, trailing gains by Nvidia and Broadcom as chip stocks rallied. Sources said Intel and AMD warned Chinese customers of longer waits and higher prices for some server CPUs, with Intel lead times reaching six months. Intel said China accounts for over 20% of its revenue. Investors await key U.S. jobs and inflation data next week.
IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

7 February 2026
IRS staffing has dropped to 2021 levels as the 2026 tax filing season begins, according to a Treasury watchdog. The agency faces a backlog of about 2 million returns, 129% above pre-pandemic levels. Most e-filers using direct deposit still get refunds within 21 days, but paper filings and amended returns could see delays. The IRS lowered its call-answer target to 70% for this season.
Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

7 February 2026
Plug Power shares rose 11.6% Friday to $2.08 after a sharp drop the previous day, as attention shifted to a Feb. 17 shareholder vote on expanding authorized shares. The company failed to secure enough votes earlier this week and is urging overseas holders to participate. CEO Andy Marsh cited difficulties for European investors in casting ballots. A reverse stock split remains possible if the proposal fails.
Go toTop